Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06139224 · ClinicalTrials.gov registry record · NA
Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection
A NA study of Alcohol Use Disorder and Human Immunodeficiency Virus, sponsored by Rush University Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06139224: Recruiting NA study of Alcohol Use Disorder and Human Immunodeficiency Virus, sponsored by Rush University Medical Center.
NCT06139224 is a NA study of Alcohol Use Disorder and Human Immunodeficiency Virus that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 20 participants, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06139224, a NA study of Alcohol Use Disorder and Human Immunodeficiency Virus, is actively recruiting participants, sponsored by Rush University Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Alcohol use disorder (AUD) has been associated with high prevalence of inflammation-associated co-morbidities in people living with HIV even those receiving effective antiretroviral therapy (ART). Our preliminary data support a model in which the combined insult of AUD and HIV on the gut, specifically on the microbiota and intestinal barrier integrity, exacerbates inflammation. Our preliminary data using intestinal organoids also suggest a potential mechanism for AUD-mediated changes in the gut barrier function during HIV; the intestines of HIV+ individuals have low resilience to alcohol induced intestinal barrier disruption caused by high levels of oxidative stress. Finally, our preliminary data also suggest a potential approach to enhance the integrity of the intestinal barrier and reduce gut derived inflammation in people living with HIV with/without AUD- short chain fatty acid prebiotics. These prebiotics prevent alcohol mediated adverse effects on the intestinal barrier and inflammation by preventing oxidative stress. These prebiotics are safe and decrease gut inflammation in humans. 20 HIV+ ART+ (10 AUD- and 10 AUD +), will be recruited for a prebiotic intervention. This is a proof-of-concept observational study to establish a causal link between microbiota-gut and HIV pathology during ART by asking whether modifying microbiota and gut milieu impacts intestinal barrier function, systemic inflammation, and brain pathology in HIV+ people. Participants will have two study visits, where stool collection and blood draw will be collected, as well as questionnaires. These participants are part of the larger observation study (n=160), which will test the hypothesis that intestines from HIV+ individuals have lower resilience to alcohol mediated gut barrier disruption than intestines from HIV-negative controls. We will recruit the following groups of participants: HIV+ ART+ AUD-; HIV+ ART+ AUD+; HIV- AUD- ; HIV- AUD+. Blood, urine, stool, and intestinal biopsies will b
Primary Outcome
Measure the permeation of sugar probes following an oral test dose of sugars as this is standard for evaluating intestinal barrier integrity
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT 10 day prebiotic consumption
Study Locations (1)
Illinois
- Ali Keshavarzian - Chicago, IL 60612
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-03-05 |
| Est. Completion | 2029-08-31 |
| Phase | NA |
What NCT06139224 shows while recruiting
NCT06139224 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 328-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which 10 day prebiotic consumption is the first listed.
NCT06139224 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06139224 about?
NCT06139224 is a clinical study titled "Gut Microbiota-Mediated Inflammatory Interactions Between AUD and HIV Infection". Alcohol use disorder (AUD) has been associated with high prevalence of inflammation-associated co-morbidities in people living with HIV even those receiving effective antiretroviral therapy (ART). Our preliminary data support a model in which the combined insult of AUD and HIV on the gut, specifical...
What is the current status of trial NCT06139224?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-03-05. Estimated completion is 2029-08-31.
What conditions does trial NCT06139224 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Human Immunodeficiency Virus.
What interventions are being tested in trial NCT06139224?
The interventions under investigation include: 10 day prebiotic consumption (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06139224?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06139224 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06139224's enrollment target sits among peer trials
20 165th of 184 higher than 15 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
AAT for Alcohol Use Disorder in Veterans
RECRUITING · NA
-
Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes
RECRUITING · NA
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI